Zalgen has core competency in the development of platforms for generation of high quality recombinant proteins from difficult-to-express genes. The firm's approaches are supported by the development of first-to-field-use rapid diagnostic tests for Lassa hemorrhagic fever (LHF) by a consortium of academic, institutional, and biotechnology entities, led by one of Zalgens' founders, These diagnostics are changing the understanding of epidemiological, immunological, and basic research notions in LHF, contributing toimprovements in the management and successful outcome of this viral disease. Principals of the firm have developed effective methods for production of Lassa virus-like particles (VLP), which are empty and non-infectious virions containing all the immunologically relevant viral proteins in quasi-native conformation. Lassa VLP are being tested as possible next generation vaccine platforms for LHF, and have shown efficacy in preliminary in vivo studies. This VLP technology has broad applications in vaccine and diagnostic platform development for a wide array of enveloped viruses. These two programs are factors in the development of first-in-class immunotherapeutics for prophylaxis and treatment of LHF. he first three fully human monoclonal antibodies, administered in single or cocktail formats have demonstrated remarkable efficacy in relevant animal models in Biosafety Level-4 (BSL-4) settings. Zalgen
